-
Something wrong with this record ?
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
AW. Langerak, M. Ritgen, V. Goede, S. Robrecht, J. Bahlo, K. Fischer, M. Steurer, M. Trněný, SP. Mulligan, UJM. Mey, K. Trunzer, G. Fingerle-Rowson, K. Humphrey, S. Stilgenbauer, S. Böttcher, M. Brüggemann, M. Hallek, M. Kneba, JJM. van Dongen,
Language English Country United States
Document type Clinical Trial, Phase III, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1946 to 1 year ago
Freely Accessible Science Journals
from 1946 to 1 year ago
Open Access Digital Library
from 1946-01-01
Open Access Digital Library
from 1946-01-01
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- Chlorambucil therapeutic use MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell diagnosis drug therapy epidemiology MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Comorbidity MeSH
- Middle Aged MeSH
- Humans MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Antineoplastic Agents therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Neoplasm, Residual diagnosis drug therapy epidemiology MeSH
- Rituximab therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Letter MeSH
- Clinical Trial, Phase III MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
Charles University Hospital Prague Czech Republic
Department of Hematology University of Schleswig Holstein Kiel Germany
Division of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Internal Medicine 3 University of Ulm Ulm Germany
Kantonsspital Graubünden Chur Switzerland
Pharma Development Oncology F Hoffmann La Roche Ltd Basel Switzerland
Pharma Development Oncology Roche Products Ltd Welwyn United Kingdom
Royal North Shore Hospital University of Sydney Sydney Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045128
- 003
- CZ-PrNML
- 005
- 20250108120507.0
- 007
- ta
- 008
- 200109s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/blood-2018-03-839688 $2 doi
- 035 __
- $a (PubMed)30455380
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Langerak, A. W., $u Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. $d 1967- $7 xx0310084
- 245 10
- $a Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab / $c AW. Langerak, M. Ritgen, V. Goede, S. Robrecht, J. Bahlo, K. Fischer, M. Steurer, M. Trněný, SP. Mulligan, UJM. Mey, K. Trunzer, G. Fingerle-Rowson, K. Humphrey, S. Stilgenbauer, S. Böttcher, M. Brüggemann, M. Hallek, M. Kneba, JJM. van Dongen,
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a chlorambucil $x terapeutické užití $7 D002699
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x epidemiologie $7 D015451
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a reziduální nádor $x diagnóza $x farmakoterapie $x epidemiologie $7 D018365
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rituximab $x terapeutické užití $7 D000069283
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a dopisy $7 D016422
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ritgen, Matthias $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Goede, Valentin $u Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany. German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Robrecht, Sandra $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Bahlo, Jasmin $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Fischer, Kirsten $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Steurer, Michael $u Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Trněný, Marek $u Charles University Hospital, Prague, Czech Republic.
- 700 1_
- $a Mulligan, Stephen P $u Royal North Shore Hospital, University of Sydney, Sydney, Australia.
- 700 1_
- $a Mey, Ulrich J M $u Kantonsspital Graubünden, Chur, Switzerland.
- 700 1_
- $a Trunzer, Kerstin $u Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Fingerle-Rowson, Günter $u Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Humphrey, Kathryn $u Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.
- 700 1_
- $a Stilgenbauer, Stephan $u Internal Medicine III, University of Ulm, Ulm, Germany.
- 700 1_
- $a Böttcher, Sebastian, $d 1971- $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany. Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany. $7 xx0327357
- 700 1_
- $a Brüggemann, Monika $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Hallek, Michael $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany. Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases, University of Cologne, Cologne, Germany; and.
- 700 1_
- $a Kneba, Michael $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a van Dongen, Jacques J M $u Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
- 773 0_
- $w MED00000807 $t Blood $x 1528-0020 $g Roč. 133, č. 5 (2019), s. 494-497
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30455380 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20250108120502 $b ABA008
- 999 __
- $a ok $b bmc $g 1483397 $s 1083801
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 133 $c 5 $d 494-497 $e 20181119 $i 1528-0020 $m Blood $n Blood $x MED00000807
- LZP __
- $a Pubmed-20200109
